Orexigen's (NASDAQ:OREX) news this week wasn't all bad -- after all, it looks like drug Contrave is a good bet for approval, the market's unhappiness about the FDA's delayed PDUFA date notwithstanding.

The delay in potential approval was tied to the need to find an agreement about post-marketing requirements. That seems to imply that the drug will be...approved to be marketed. Nonetheless, given the commercialization troubles competitors Arena Pharmaceuticals (NASDAQ:ARNA) and VIVUS (NASDAQ:VVUS) have had, some caution is appropriate when considering potential sales.

In this week's health care-focused episode of Where The Money Is, health care analysts Michael Douglass and David Williamson lay out why they still prefer to wait on the sidelines.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.